Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/4785
Title: A systematic review of secretory carcinoma of the salivary gland: where are we?
Authors: Melo, Andreia Cristina de
Alves, Lísia Daltro Borges
Farinha, Thayana Alves
Araújo, Luiz Henrique de Lima
Thiago, Leandro de Souza
Dias, Fernando Luiz
Antunes, Héliton Spíndola
Eisenberg, Ana Lucia Amaral
Thuler, Luiz Claudio Santos
Goldemberg, Daniel Cohen
Keywords: Revisão Sistemática
Systematic Review
Carcinoma
Carcinoma
Proteínas e Peptídeos Salivares
Salivary Proteins and Peptides
Issue Date: 2021
Publisher: Oral and Maxillofacial Pathology
Citation: MELO, Andreia Cristina de et al. A systematic review of secretory carcinoma of the salivary gland: where are we? Oral and Maxillofacial Pathology, v. 132, n. 4, p. 143-152, oct. 2021.
Abstract: The aim of this systematic review was to describe the epidemiology, diagnostic criteria, differential diagnosis, treat ment, prognostic factors, and treatment outcomes of secretory carcinoma. Study Design. A comprehensive search of Lilacs, PubMed, Science Direct, and Web of Science databases was conducted to iden tify all case reports, letter to the editor, and histopathologic reclassifications regarding salivary gland secretory carcinoma pub lished in English, Spanish, French, and Portuguese. Results. The final analysis included 119 studies, which totaled 642 secretory carcinoma diagnoses, with 239 case reports and 403 diagnostic reclassifications, mostly in the United States. The age range was 5 to 87 years, and cases were predominantly in males (58.7%) and mostly affecting the parotid glands (73.7%). The disease usually presents as a slow-growing, painless mass. The main differential diagnosis is acinic cell carcinoma, and the tumor is usually treated with surgery. The prognosis is considered favor able, although there have been reports of local recurrences, distant metastases, and deaths. Conclusions. It is important that clinicians become aware of this salivary gland neoplasm and report clinical data, clinical course, management and long-term follow-up. There is an urgent need to conduct more clinical trials, especially on tropomyosin receptor kinase (TRK) inhibitors and other potential target therapy modalities.
Description: p. 143-152.: tab. p&b.
URI: http://sr-vmlxaph03:8080/jspui/handle/123456789/4785
ISSN: 2212-4403
Appears in Collections:Artigos de Periódicos da área de Ginecologia



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.